ReviewFrontiers in pharmacology2026
The mechano-immunological barrier in fibrosis-associated lung cancer: targeting matrix stiffness and the Piezo1 axis for microenvironment normalization.
Review in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Current Perspectives on 2D and 3D Cell Culture Models in Cancer Research: Molecular Determinants of Tumor Biology and Therapeutic Response.Current issues in molecular biology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
While mechanotransduction influences various lung cancer subtypes, this review focuses specifically on fibrosis-associated non-small cell lung cancer (NSCLC), where the progression from pulmonary fibrosis to malignancy is mediated by aberrant mechanotransduction. Progressive extracellular matrix (ECM) stiffening (8-25 kPa), mediated by lysyl oxidase (LOX)-dependent collagen crosslinking, establishes a "mechano-immunological barrier." This barrier promotes malignant transformation and limits the efficacy of immunotherapy. Piezo1, a mechanically-activated cation channel, regulates this physical remodeling of the tumor microenvironment (TME). In the stiffened fibrotic stroma, mechanical tension activates Piezo1, causing intracellular Ca
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.